Güncellemeler
Neler yeni
İçerik eklemeleri, yeni özellikler ve düzeltmeler — WhatIsLCA'de neyin değiştiğini takip edebilmeniz için düzenli olarak güncellenir.
- İyileştirme
A cleaner, faster research timeline
- The timeline now shows compact, title-only cards, so busy years (like 2026, with ten milestones) fit on screen without crowding.
- Hover a milestone — or tap it on mobile — to open a detail card with the full description, the genes involved, and its sources. It stays open while you read and closes when you move away, tap elsewhere, or press Escape.
Değişeni gör - İçerik
Upcoming conferences added to the timeline
- The timeline now includes upcoming LCA-relevant conferences, each marked with an “Upcoming” badge (which disappears automatically once the event has passed) and linking to the official event page.
- For families: Hope in Focus's LCA Community Conference (8–11 July 2027, Hartford, CT) — a family-focused gathering for people living with LCA, with travel scholarships available.
- For researchers and clinicians: ESGCT 2026 (Hamburg), ARVO 2027 (San Diego), ASGCT 2027 (Philadelphia), and EURETINA 2027 (Copenhagen) — the meetings where new LCA gene-therapy data is presented.
Değişeni gör - İçerik
September 2026 research update — new milestones and honest status corrections
- We reviewed the latest LCA research and refreshed the site — adding new milestones and, just as importantly, stating setbacks plainly rather than only the positive headlines.
- New — LCA5: Opus Genetics completed enrollment in its registrational Phase 3 of OPGx-LCA5 (August 2026); participants are in the six-month run-in, with dosing expected in Q4 2026 — a path toward what could be the first approved therapy for LCA5.
- New — LCA16 (KCNJ13): a 2026 peer-reviewed proof-of-concept (Signal Transduction and Targeted Therapy) using an engineered “suppressor” tRNA to read through the W53X nonsense mutation and restore the Kir7.1 channel.
- New — LCA4 (AIPL1): the MeiraGTx therapy now has an international name, meduretgene parvec (medu-vec), and is licensed to Eli Lilly; we corrected the linked AIPL1 trial record to the study now recruiting in China (LX107).
- New — LCA2 (RPE65): next-generation RPE65 gene therapies are now in trials beyond Luxturna, including HuidaGene’s HG004 (STAR, Phase 1/2).
- Corrected — CRISPR / EDIT-101 (LCA10): proof of concept was shown, but Editas paused the program in 2022 (too few people carry the exact target mutation) and is seeking a partner; it is not currently progressing.
- Corrected — Sepofarsen (LCA10): the first pivotal trial (ILLUMINATE) missed its endpoint in 2022 and was revived as the redesigned Phase 3 HYPERION (2025). ATSN-101 (LCA1) claims were checked against the 2024 Lancet paper and tightened.
- All the new milestones and the ILLUMINATE setback are now on the timeline.
Değişeni gör - Yeni
“The Treatment Window” — why timing matters
- A new interactive page explains why gene therapy can only help photoreceptors that are still alive, so there is a window of opportunity that differs by LCA gene — with an age slider that shows where each gene's window typically sits.
- It ties the science to something families can act on: getting an exact genetic diagnosis early, and how newborn genome screening could find treatable blindness before vision is lost. Framed honestly as an illustrative guide, not a personal prognosis.
Değişeni gör - İçerik
A faster FDA path for the LCA5 gene therapy
- The LCA5 page and timeline now cover Opus Genetics' July 2026 FDA alignment on a streamlined Phase 3 for OPGx-LCA5: participants serve as their own control after a six-month run-in, the primary endpoint is a ≥7 dB gain in retinal sensitivity, and a marketing application may be filed on six-month data (with RMAT designation opening an accelerated route).
- The “From Lab to Patient” page gained a short explainer on how the development journey can be made faster for ultra-rare diseases, using this alignment as a real example.
Değişeni gör - Yeni
“From Lab to Patient” — how a gene therapy is developed
- A new page maps the whole journey from discovery to an approved treatment — animal studies, IND-enabling work, human trials, and regulatory review — as an easy-to-follow roadmap.
- It also shows the tracks that run in parallel (funding, FDA designations, manufacturing, and patient recruitment), plus a plain-language walkthrough of how patients actually join a trial.
Değişeni gör - İçerik
RPGRIP1 (LCA6) gene-therapy program and its evidence
- The LCA6 (RPGRIP1) type page now covers Odylia Therapeutics' OT-004 — an AAV (Anc80) gene-augmentation therapy in late-stage preclinical development, with FDA Orphan Drug and Rare Pediatric Disease designations and no clinical trial registered yet.
- Added the academic proof-of-concept behind it: photoreceptor rescue in RPGRIP1-knockout mice (Pawlyk 2005/2010) and durable cone-vision rescue in the RPGRIP1-deficient dog (Lhériteau 2014), plus a 228-patient natural-history reference (Beryozkin 2021).
- Three RPGRIP1 milestones added to the timeline (2005 mouse, 2014 dog, 2021 FDA designations).
Değişeni gör - İçerik
Preclinical and early-trial status added for 11 more LCA genes
- Reviewed every remaining LCA type for gene-therapy activity and added the peer-reviewed evidence behind it: academic proof-of-concept in animal or organoid models for SPATA7 (LCA3), CRX (LCA7), NMNAT1 (LCA9), RD3 (LCA12), TULP1 (LCA15), KCNJ13 (LCA16), IQCB1/NPHP5, IFT140, and CABP4.
- Documented the two with human data: LRAT (LCA14), an oral-retinoid Phase 1b that later stalled, and PRPH2 (LCA18), an individualized single-patient antisense trial — each described honestly with its limits.
- Genes with no gene-therapy proof yet (IMPDH1, GDF6, USP45, CCT2, CLUAP1, DTHD1, OTX2) were deliberately left unchanged — no claim without a citation.
- The nine animal/organoid proof-of-concept studies were also plotted on the timeline (2013–2026), showing how gene-therapy research now spans many LCA genes.
Değişeni gör - İçerik
Added a 2026 Lancet review as an overview reference
- The “How Treatments Work” page now cites a peer-reviewed Lancet review (2026) of inherited retinal degenerations and their emerging gene, cell, optogenetic, and implant therapies — an authoritative overview covering all the approaches described.
Değişeni gör - İyileştirme
Treatment diagrams now play automatically
- On the “How Treatments Work” page, each mechanism’s steps advance on their own with a progress bar — and pause the moment you click, so you can explore at your own pace.
Değişeni gör - Yeni
Report an error on any page, and an editorial-standards page
- Every page now has a one-click way to report an inaccuracy — via a form (no account needed) or our public community repository.
- A new “Editorial standards” page explains how we source, review, and keep content current.
- Pages now show a medical-review status so you can see how thoroughly each has been checked.
Değişeni gör - Yeni
“How Treatments Work” — an interactive 3D explainer
- A new page walks through gene augmentation, gene editing (CRISPR), RNA therapy, stem-cell therapy, and optogenetics with step-by-step 3D visuals and a plain-language comparison.
Değişeni gör
Güncel olmayan bir şey mi gördünüz? Herhangi bir sayfanın altındaki bildirim butonunu kullanın.